Choose Semaglutide If You have established cardiovascular disease (prior heart attack, stroke, stent, peripheral artery disease) You're over 50 with multiple cardiovascular risk factors (hypertension, high LDL, smoking history, family history) You've already lost most of the weight you want to lose and you're switching from short-term weight loss to long-term metabolic protection You want the longest-running real-world safety data on a GLP-1 Choose Tirzepatide If Your primary goal is maximum weight loss in the shortest timeframe You don't have established cardiovascular disease You've plateaued on semaglutide and need stronger appetite suppression You tolerate tirzepatide better (some people get less GI upset on dual agonism) What's Still Available After the FDA Crackdown 503A compounding pharmacies continue to prepare both peptides for documented medical need
This is why careful planning matters during treatment
What is the value of the L-carnitine industry in North America
Breakthrough science or a commercially elegant shortcut
Bugianesi, E., Moscatiello, S., Ciaravella, M
According to NICE Technology Appraisal 875 (TA875) , Wegovy is available on the NHS only through specialist weight management services for people who meet specific criteria, generally including a BMI of 35 kg/m or above with weight-related comorbidities (with lower thresholds for certain ethnic groups)
